Research output on immune checkpoint inhibitor-associated cardiotoxicity has surged from 9 publications in 2016 to 236 in 2025, indicating heightened academic focus.

ClinicalJune 27, 2026

Rising Bone Cancer Incidence Highlights Need for Improved Surgical Outcomes

The incidence of malignant bone tumors has increased significantly, with a projected rise in cases by 2050.

RegulatoryJune 7, 2026

FDA Grants AP Status for MESNA ANDA203364 Submission by RISING

The FDA has granted an Abbreviated Approval (AP) status for the MESNA ANDA203364 submission from RISING.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Bone Cancer →

Therapeutic areas

Bone Cancer →

Immune Checkpoint Inhibitors →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.